VEVYE (cyclosporine)

Self-Administration – Ophthalmic

Diagnosis considered for coverage:
  • Indicated for the treatment of the signs and symptoms of dry eye disease
Coverage Criteria:

For diagnosis of dry eye disease:

  • Diagnosis of dry eye disease; AND
  • Trial and failure, contraindication, or intolerance to BOTH of the following:
    • Restasis (cyclosporine 0.05%) 
    • Xiidra (lifitegrast)
Reauthorization Criteria:

For diagnosis of dry eye disease:

  • Patient demonstrates positive clinical response to therapy (e.g., increased tear production or improvement in dry eye symptoms)
Dosing:

Dry eye disease:

  • Instill one drop of Vevye twice a day in each eye approximately 12 hours apart
Coverage Duration: 
  • Initial: 1 year
  • Reauthorization: 1 year
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information: 
  • If used with other eye drops, a 15-minute interval between products should occur
  • Clear, colorless, non-preserved ophthalmic solution containing cyclosporine 0.1% (1 mg/mL), delivering 0.01 mg of cyclosporine per one drop (0.01 mL)
  • Safety and effectiveness in pediatric patients below the age of 18 years have not been established
Policy Updates:
  • Effective 6/1/2024 – New policy approved by WHA P&T Committee. (P&T, 5/21/2024) 
References:
  1. Vevye Prescribing Information. Alliance Medical Products, Inc. Irvine, CA. May 2023. 
  2. American Academy of Ophthalmology. Dry Eye Syndrome Preferred Practice Pattern. November 2018. Available at: https://www.aao.org/preferred-practice-pattern/dry-eye-syndrome-ppp-2018. Accessed January 6, 2024. 
  3. Xiidra [package insert]. Hanover, NJ: Novartis Pharmaceuticals Corporation: June 2020. 
  4. Restasis [package insert]. Irvine, CA: Allergan, Inc.; July 2017 
  5. Restasis MultiDose [package insert]. Irvine, CA: Allergan, Inc.; October 2016. 
  6. Tyrvaya [package insert]. Princeton NJ: Oyster Point Pharma, Inc; October 2021 
  7. Cequa [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; December 2022. 
  8. Miebo [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc; May 2023. 
  9. ClinicalTrials.gov. CyclASol for the Treatment of Moderate to Severe dry-eye disease (DED). Avaialble at: https://www.clinicaltrials.gov/study/NCT02617667?cond=NCT02617667&rank=1. Accessed January 6, 2024. 
  10. ClinicalTrials.gov. ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED). Avaialble at: https://www.clinicaltrials.gov/study/NCT04523129?cond=nct04523129&rank=1. Accessed January 6, 2024.

Last review date: June 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone